Serotyping: why, when, and how to assess your AAV therapeutic to get it approved

When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved.

As part of the CQA assessment, you need to make sure your vector is intact, that its serotype — or identity — is correct, and that your vector preps remain stable.  

In this video, learn why and when serotyping impacts AAV vector development. Discover how to assess your vector serotype so you can improve processes, monitor vector quality, and produce a more potent and effective AAV therapeutic.

Join this discussion with Léa Valla and Dr. Stefanie Kall,  AAV Applications Team at NanoTemper Technologies.

 

 

Previous Video
How 2bind identifies the best buffer for a vaccine antigen target with Prometheus Panta
How 2bind identifies the best buffer for a vaccine antigen target with Prometheus Panta

Discover how 2bind applied multi-parameter characterization from a single experiment to find the optimal bu...

Up next
See the new Monolith — characterize your most challenging interactions
See the new Monolith — characterize your most challenging interactions